Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

NCT07581002 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07581002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07581002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 30, 2026
Completion date
June 30, 2032
Enrollment
660 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia